Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children for you to read. Along with our medical data and news we also list Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Clinical Trials, which are updated daily. BioPortfolio also has a large database of Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Companies for you to search.
TUESDAY, March 26, 2019 -- If the cacophony of children screaming and throwing tiny plastic balls everywhere hasn't prompted you to forgo ball pits, a new study may just send you scurrying for the door. The research found that ball pits in physical...
TUESDAY, March 26, 2019 -- For euthyroid women with thyroid peroxidase antibodies and a history of miscarriage or infertility, levothyroxine does not result in an increased rate of live births versus placebo, according to a study published online...
(MedPage Today) -- Peritumoral data may accurately reflect tumor microenvironment, assist treatment selection
Individuals with a calcium score above 100 should think twice about stopping aspirin. The higher the calcium score the more likely aspirin benefit exceeds harm. PALO ALTO, Calif. (PRWEB) March 26, 2019 Leading preventive cardiologists and academic cardiovascular specialists from the Society for Heart Attack Prevention and Eradication (SHAPE), (http://www.shapesociety.org), a non-profit organizati...
LP-10, which has received FDA Orphan Drug designation, has now obtained IND approval for Phase-2a, multi-center, double-blind, controlled, clinical trial for hemorrhagic cystitis. Lipella Pharmaceuticals Inc., a clinical stage biopharmaceutical company based in Pittsburgh, PA, anno
Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel...
Building on Kohl’s commitment to family health and wellness, funding will improve access to critical mental health services for Wisconsin children and families In support of the company’s broader Corporate Social Responsibility (CSR) platform focused on family health and wellness, Kohl's (NYSE: KSS) today announced it will donate $5 milli...
Aphios Corporation today announced that it has been granted European Patent No. 2 925 315 B1 entitled “Bryoid Compositions, Methods of Making and Use Thereof,” for the composition of matter of a novel Bryostatin, method of manufacturing and for use in the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Down’s syndrome, H...
- Data demonstrate how an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy - Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors,
Company to present data sets from recently launched high-parameter, spatial biology imaging platforms for discovery through clinical and translational research Akoya Biosciences, Inc., today announced that data from its new line of multiplex immunofluorescence imaging platforms for high-parameter, spatially resolved biomarker analysis will be presented...
Researchers will highlight work in BRCA-deficient and rare pediatric cancers Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and two oral presentations to highlight its enhanced o...
Innovative device easily removes pesky skin tags; achieve dermatologist-quality results without the cost Claritag™, the leading beauty solution for at-home skin tag removal, has optimized the design of its cryogenics skincare product. Developed by leading dermatologists and skincare professionals, Claritag’s innovative proprietary te
This study evaluated the clinical performance of the Elecsys HIV combi PT assay, which was designed with a pretreatment step to enhance early detection and increase sensitivity and specificity. American Journal of Clinical Pathology
This study examined the prevalence and characteristics of clinical sleep disorders in patients experiencing early psychosis. Schizophrenia Bulletin
This study evaluated predictive models for patient-reported outcomes in elective degenerative spinal surgery with respect to study design, accuracy, reliability, variance, and utility. Neurosurgical Focus
Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.
A consultant neurosurgeon was negligent in giving a patient antithrombotic treatment only three hours after spinal surgery, the Court of Appeal has ruled.1Three senior judges unanimously dismissed...
Can-Fite's shares hit after failure of mid-stage liver cancer study of namodenoson https://www.firstwordpharma.com/node/1631373 $CANF
BriaCell Therapeutics Corp. (TSXV:BCT) (OTC:BCTXF) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it is finalizing the analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT™, with pembrolizumab (KEYTRUDA®; manufactur...
Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease negative complete responses
The most comprehensive study yet of this technique found no cases of breast cancer at 53 months, suggesting it is safe. Medscape Medical News
Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue Ozempic (oral semaglutide), indicating that the drug achieved “superior reductions” in blood sugar, and body weight compared to MSD’s Januvia (sitagliptin 100 mg). The therapy was tested in in type 2 diabetes patients whose condition was inadequately controlled with metformin, with or w...
Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients
Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center tr...
Aldeyra's experimental drug reproxalap hits main goal in Phase III allergic conjunctivitis study https://www.firstwordpharma.com/node/1631347 $ALDX
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key related findings as follows: ...